Chk1及其抑制剂调控肿瘤作用机制研究(6)
[32]Vincelette ND，Ding H，Huehls AM，et al.Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo[J].Scientific Reports，2019，9(1)：3617.
[33]Preet R，Siddharth S，Satapathy SR，et al.Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade[J].Biochemical Pharmacology，2016，105(1)：23-33.
[34]Hauge S，Naucke C，Hasvold G，et al.Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage+in S-phase due to distinct regulation of CDK activity and CDC45 loading[J].Oncotarget，2017，8(7)：10966-10979.
[35]Booth L，Roberts J，Poklepovic A，et al.The Chk1 inhibitor，SRA737，synergizes with niraparib to kill cancer cells via multiple cell death pathways[A]//Proceedings of the American Association for Cancer Research Annual Meeting[C].2018.
[36]Yin Y，Shen Q，Zhang P，et al.Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer[J].American Journal of Cancer Research，2017，7(3)：473., 百拇医药(于祥菊 宋碧莹 刘滢 吕冬霞)
[33]Preet R，Siddharth S，Satapathy SR，et al.Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade[J].Biochemical Pharmacology，2016，105(1)：23-33.
[34]Hauge S，Naucke C，Hasvold G，et al.Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage+in S-phase due to distinct regulation of CDK activity and CDC45 loading[J].Oncotarget，2017，8(7)：10966-10979.
[35]Booth L，Roberts J，Poklepovic A，et al.The Chk1 inhibitor，SRA737，synergizes with niraparib to kill cancer cells via multiple cell death pathways[A]//Proceedings of the American Association for Cancer Research Annual Meeting[C].2018.
[36]Yin Y，Shen Q，Zhang P，et al.Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer[J].American Journal of Cancer Research，2017，7(3)：473., 百拇医药(于祥菊 宋碧莹 刘滢 吕冬霞)